BR112021001376A2 - preparação farmacêutica, e usos de 2-amino-2-[4-(3-benziloxifeniltio)-2-clorofenil]etil-propano-1,3-diol, ou um sal farmaceuticamente aceitável do mesmo - Google Patents

preparação farmacêutica, e usos de 2-amino-2-[4-(3-benziloxifeniltio)-2-clorofenil]etil-propano-1,3-diol, ou um sal farmaceuticamente aceitável do mesmo Download PDF

Info

Publication number
BR112021001376A2
BR112021001376A2 BR112021001376-8A BR112021001376A BR112021001376A2 BR 112021001376 A2 BR112021001376 A2 BR 112021001376A2 BR 112021001376 A BR112021001376 A BR 112021001376A BR 112021001376 A2 BR112021001376 A2 BR 112021001376A2
Authority
BR
Brazil
Prior art keywords
chlorophenyl
diol
amino
benzyloxyphenylthio
propane
Prior art date
Application number
BR112021001376-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Claudia Corrado
Christoph BUCHER
Julie Jones
Peter Gergely
Original Assignee
Priothera Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Limited filed Critical Priothera Limited
Publication of BR112021001376A2 publication Critical patent/BR112021001376A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112021001376-8A 2018-07-27 2019-07-26 preparação farmacêutica, e usos de 2-amino-2-[4-(3-benziloxifeniltio)-2-clorofenil]etil-propano-1,3-diol, ou um sal farmaceuticamente aceitável do mesmo BR112021001376A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018141411 2018-07-27
JP2018-141411 2018-07-27
JP2019036598 2019-02-28
JP2019-036598 2019-02-28
PCT/JP2019/029524 WO2020022507A1 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Publications (1)

Publication Number Publication Date
BR112021001376A2 true BR112021001376A2 (pt) 2021-04-20

Family

ID=69181631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021001376-8A BR112021001376A2 (pt) 2018-07-27 2019-07-26 preparação farmacêutica, e usos de 2-amino-2-[4-(3-benziloxifeniltio)-2-clorofenil]etil-propano-1,3-diol, ou um sal farmaceuticamente aceitável do mesmo

Country Status (11)

Country Link
US (1) US20210283073A1 (https=)
EP (1) EP3831370A4 (https=)
JP (1) JP7389486B2 (https=)
KR (1) KR102948053B1 (https=)
CN (2) CN112512516A (https=)
AU (1) AU2019311609B2 (https=)
BR (1) BR112021001376A2 (https=)
IL (1) IL280451B2 (https=)
MX (1) MX2021001039A (https=)
TW (1) TWI899057B (https=)
WO (1) WO2020022507A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022162409A1 (en) 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators
AU2022214268A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
PL1932522T3 (pl) 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2252615A1 (en) * 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
US10407727B2 (en) * 2013-01-30 2019-09-10 Memorial Sloan Kettering Cancer Center Donor KIR3DL1 and HLA-B subtypes and leukemia control in HLA-compatible allogenic hematopoietic stem cell transplantation
BR112015019197A2 (pt) * 2013-02-20 2017-07-18 Kyorin Seiyaku Kk tratamento de doença de enxerto versus hospedeiro em pacientes transplantados
US10154989B2 (en) * 2015-09-17 2018-12-18 Emory University Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof
ES2917208T3 (es) 2016-03-08 2022-07-07 Priothera Ltd Tratamiento de pacientes con trasplante de células madre hematopoyéticas

Also Published As

Publication number Publication date
WO2020022507A1 (ja) 2020-01-30
CN112512516A (zh) 2021-03-16
KR20210040954A (ko) 2021-04-14
CN120284929A (zh) 2025-07-11
EP3831370A1 (en) 2021-06-09
AU2019311609B2 (en) 2024-09-26
AU2019311609A1 (en) 2021-02-04
IL280451B1 (en) 2025-06-01
JPWO2020022507A1 (ja) 2021-08-05
IL280451B2 (en) 2025-10-01
MX2021001039A (es) 2021-04-12
TW202011948A (zh) 2020-04-01
IL280451A (en) 2021-03-25
US20210283073A1 (en) 2021-09-16
KR102948053B1 (ko) 2026-04-06
CA3106608A1 (en) 2020-01-30
JP7389486B2 (ja) 2023-11-30
TWI899057B (zh) 2025-10-01
EP3831370A4 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
Ayash et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
CN109641002B (zh) 血液癌症的组合治疗
US20260115223A1 (en) Methods of treating myelodysplastic syndrome
BR112021001376A2 (pt) preparação farmacêutica, e usos de 2-amino-2-[4-(3-benziloxifeniltio)-2-clorofenil]etil-propano-1,3-diol, ou um sal farmaceuticamente aceitável do mesmo
HUP0302130A2 (hu) Kombinációs gyógyszerkészítmény és eljárás az előállításukra
CN112165945A (zh) 治疗淋巴样恶性疾病之方法
MXPA06013559A (es) Tratamiento de linfoma de celula t usando 10-propargil-10-deazaaminopterina.
CA3106608C (en) Preparation for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
Presant et al. Amphotericin B plus 1, 3‐BIS (2‐chloroethyl)‐1‐nitrosourea (BCNU‐NSC NO. 409962) in advanced cancer. Phase I and preliminary phase II results
Takahashi et al. Recombinant human granulocyte colony‐stimulating factor (G‐CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard‐risk myeloid leukemia
KR20140138885A (ko) 급성 골수성 백혈병 또는 만성 골수성 백혈병을 치료하기 위한 신규 조합물
HK40050286A (en) Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
WO2025166537A1 (en) Methods of treatment using an ezh2 modulator
EA048825B1 (ru) Препарат для подавления рецидива гематологической злокачественной опухоли у пациентов, перенесших трансплантацию гемопоэтических стволовых клеток
WO2024137356A1 (en) Methods for treatment of bone marrow failure and related conditions
BR122024018240B1 (pt) Uso de imetelstat e abt-199, uso de imetelstat de sódio e abt-199, e método in vitro para induzir apoptose
BR112019002025B1 (pt) Usos de uma combinação de imetelstat e abt-199 ou um sal farmaceuticamente aceitável do mesmo, kit, método in vitro para induzir apoptose e composição farmacêutica
BR122024018240A2 (pt) Uso de inibidores de telomerase e de bcl-2 e suas combinações, uso de imetelstat e abt-199 ou sais dos mesmos e suas combinações, kit, método in vitro para induzir apoptose, e composição farmacêutica

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]